Sirolimus for Injection (Albumin Bound)

DRUG3 trials

Sponsors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions

Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)Advanced Solid TumorsGastroenteropancreatic Neuroendocrine Tumors

Phase 1

A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Solid Tumors

Start: 2021-12-28End: 2024-11-30Target: 264Updated: 2022-01-25

A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa)

Start: 2022-11-08End: 2024-11-30Target: 54Updated: 2022-11-28

Phase 2

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

RecruitingNCT07165886

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Gastroenteropancreatic Neuroendocrine Tumors

Start: 2025-08-29End: 2028-08-29Target: 298Updated: 2026-04-24